Studies will use BreathID 13 C-methacetin breath test to evaluate patient response to therapy MODI’IN, Israel and MANASQUAN, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN) ...

Building on the BreathID Hp urea breath testing technology for Helicobacter pylori (H. pylori) detection, the new BreathID Hp Lab system provides cost-effective automated batch test analysis for ...

Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced new ...

TEL AVIV (Reuters) – Exalenz Bioscience, a developer of diagnostic systems that use a patient’s breath to detect gastrointestinal and liver conditions, launched BreathID Hp, a next generation device ...

Exalenz Biosciences announced a collaboration with Conatus Pharmaceuticals. The deal will find Conatus using the BreathID Methacetin Breath Test (MBT) to monitor patients in a Phase IIb clinical trial ...

Exalenz Bioscience’s flagship product is the BreathID® Hp test, a non-invasive urea in-office breath test designed to detect active H. pylori infections within minutes. Clinical studies have ...

Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a ...

Exalenz Bioscience BreathID breath test platform can accurately detect clinically significant portal hypertension in non-alcoholic steatohepatitis patients with compensated advanced chronic liver ...

CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered ...

JERSEY CITY, N.J., July 23, 2013 /PRNewswire/ -- Exalenz Bioscience (TASE: EXEN), developer of advanced diagnostic systems that use a patient's breath to detect and help manage gastrointestinal and ...